PT948614E - Novos vectores de expressão contendo genes de ligandos de moléculas acessórias e seu uso para imunomodulação e tratamento de tumores malignos e doenças auto-imunes - Google Patents
Novos vectores de expressão contendo genes de ligandos de moléculas acessórias e seu uso para imunomodulação e tratamento de tumores malignos e doenças auto-imunes Download PDFInfo
- Publication number
- PT948614E PT948614E PT97954089T PT97954089T PT948614E PT 948614 E PT948614 E PT 948614E PT 97954089 T PT97954089 T PT 97954089T PT 97954089 T PT97954089 T PT 97954089T PT 948614 E PT948614 E PT 948614E
- Authority
- PT
- Portugal
- Prior art keywords
- accessory molecule
- immunomodulation
- treatment
- malignancies
- expression vectors
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 title abstract 2
- 230000036210 malignancy Effects 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C07K14/5255—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3214596P | 1996-12-09 | 1996-12-09 | |
| US08/982,272 US7070771B1 (en) | 1996-12-09 | 1997-12-01 | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| PCT/US1997/022740 WO1998026061A2 (en) | 1996-12-09 | 1997-12-08 | Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT948614E true PT948614E (pt) | 2009-04-20 |
Family
ID=26708033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97954089T PT948614E (pt) | 1996-12-09 | 1997-12-08 | Novos vectores de expressão contendo genes de ligandos de moléculas acessórias e seu uso para imunomodulação e tratamento de tumores malignos e doenças auto-imunes |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7070771B1 (enExample) |
| EP (4) | EP2145958B1 (enExample) |
| JP (1) | JP4015201B2 (enExample) |
| CN (1) | CN1221662C (enExample) |
| AT (2) | ATE547524T1 (enExample) |
| AU (1) | AU5795798A (enExample) |
| BR (1) | BR9714004A (enExample) |
| CA (2) | CA2274498C (enExample) |
| DE (1) | DE69739220D1 (enExample) |
| DK (1) | DK0948614T3 (enExample) |
| ES (1) | ES2321246T3 (enExample) |
| IL (3) | IL130247A0 (enExample) |
| NO (2) | NO327411B1 (enExample) |
| NZ (1) | NZ336092A (enExample) |
| PT (1) | PT948614E (enExample) |
| WO (1) | WO1998026061A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| WO2000063395A1 (en) * | 1999-04-16 | 2000-10-26 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| GB9917180D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Sheffield | Cell surface receptor |
| GB0025307D0 (en) * | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| WO2002036769A2 (en) * | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| AU2003207349A1 (en) * | 2002-02-25 | 2003-09-09 | Isis Innovation Limted | Novel complexes for inducing an immune response |
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20080044393A1 (en) * | 2004-07-16 | 2008-02-21 | White Robert L | Retinal dystrophin transgene and methods of use thereof |
| US20100292309A1 (en) * | 2007-03-08 | 2010-11-18 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| US20100050276A1 (en) * | 2008-08-22 | 2010-02-25 | Brown University | Transgenic non-human animal models of apoptosis-mediated conditions |
| DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
| SI2908865T1 (sl) * | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
| WO2015148879A1 (en) * | 2014-03-27 | 2015-10-01 | The Regents Of The University Of Michigan | Cancer immunotherapy compositions and methods |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN105567679B (zh) * | 2014-10-10 | 2019-07-05 | 深圳市北科生物科技有限公司 | 可分泌型trail蛋白构建物和表达载体 |
| WO2017079297A1 (en) | 2015-11-02 | 2017-05-11 | Memgen Llc | Methods for treatment of cancer |
| US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
| CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3609581A4 (en) | 2017-04-12 | 2021-01-13 | Memgen LLC | PROCEDURE FOR CD40 AND TOLL-LIKE RECEPTOR IMMUNACTIVATION |
| SG11202007156QA (en) | 2018-02-09 | 2020-08-28 | Nat Univ Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| KR102839381B1 (ko) | 2018-08-29 | 2025-07-28 | 내셔널 유니버시티 오브 싱가포르 | 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN112725379B (zh) * | 2021-01-27 | 2024-08-13 | 上海南方模式生物科技股份有限公司 | 人源化cd40基因改造动物模型的构建方法及应用 |
| US11585330B1 (en) * | 2021-09-29 | 2023-02-21 | Halliburton Energy Services, Inc. | Flow control for geothermal well |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0251037B1 (en) | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Novel human TNF polypeptide mutants and DNAs encoding said mutants |
| JPH082315B2 (ja) | 1987-05-29 | 1996-01-17 | 財団法人相模中央化学研究所 | リンホトキシンを含む融合蛋白質 |
| DE69029970T2 (de) | 1989-08-16 | 1997-06-19 | Chiron Corp | Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen |
| US5519119A (en) | 1990-09-21 | 1996-05-21 | Ishihara Sangyo Kaisha Ltd. | Muteins of TNF pharmaceutical compositions and a method of making |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| CA2312667C (en) | 1991-10-25 | 2002-11-19 | Immunex Corporation | Novel cytokine |
| NZ251820A (en) | 1992-03-30 | 1996-07-26 | Immunex Corp | Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide |
| CZ283533B6 (cs) | 1992-04-02 | 1998-04-15 | F. Hoffmann-La Roche Ag | TNF - muteiny a způsob jejich výroby |
| ES2252732T3 (es) | 1992-05-26 | 2006-05-16 | Immunex Corporation | Nueva citoquina que une cd30. |
| AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
| US5540926A (en) | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Ｃｄ４０リガンド遺伝子の突然変異の検出および治療 |
| EP0679191B1 (en) | 1993-01-22 | 2003-12-10 | Immunex Corporation | Detection and treatment of mutations in a cd40 ligand gene |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
| JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| ATE267607T1 (de) | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| EP0739350B1 (en) | 1994-01-07 | 2008-02-27 | Mochida Pharmaceutical Co., Ltd. | Ligand that binds fas antigen |
| EP0763057B1 (en) | 1994-04-28 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Method for proliferating and differentiating b cells, and uses thereof |
| US5606023A (en) | 1994-05-24 | 1997-02-25 | Thomas Jefferson University | Mutant tumor necrosis factor proteins |
| US5759536A (en) | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
| CA2195665A1 (en) | 1994-07-22 | 1996-02-08 | Robert Frederick Geoffrey Booth | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US5888764A (en) * | 1995-01-20 | 1999-03-30 | Uab Research Foundation | Human fas gene promoter region |
| US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US7070771B1 (en) * | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
| US6016832A (en) * | 1997-04-16 | 2000-01-25 | Woodward Governor Company | Valve for controlling gas mass flow |
| EP1016721B1 (en) | 1997-09-17 | 2010-03-10 | Mochida Pharmaceutical Co., Ltd. | Fas ligand derivative |
| US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
| US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
-
1997
- 1997-12-01 US US08/982,272 patent/US7070771B1/en not_active Expired - Fee Related
- 1997-12-08 AU AU57957/98A patent/AU5795798A/en not_active Abandoned
- 1997-12-08 DE DE69739220T patent/DE69739220D1/de not_active Expired - Lifetime
- 1997-12-08 PT PT97954089T patent/PT948614E/pt unknown
- 1997-12-08 CA CA2274498A patent/CA2274498C/en not_active Expired - Fee Related
- 1997-12-08 DK DK97954089T patent/DK0948614T3/da active
- 1997-12-08 EP EP09164341A patent/EP2145958B1/en not_active Expired - Lifetime
- 1997-12-08 CN CNB971816743A patent/CN1221662C/zh not_active Expired - Fee Related
- 1997-12-08 EP EP97954089A patent/EP0948614B1/en not_active Expired - Lifetime
- 1997-12-08 IL IL13024797A patent/IL130247A0/xx active IP Right Grant
- 1997-12-08 ES ES97954089T patent/ES2321246T3/es not_active Expired - Lifetime
- 1997-12-08 NZ NZ336092A patent/NZ336092A/en not_active IP Right Cessation
- 1997-12-08 JP JP52695698A patent/JP4015201B2/ja not_active Expired - Fee Related
- 1997-12-08 CA CA2707726A patent/CA2707726C/en not_active Expired - Fee Related
- 1997-12-08 AT AT09164341T patent/ATE547524T1/de active
- 1997-12-08 AT AT97954089T patent/ATE420956T1/de not_active IP Right Cessation
- 1997-12-08 EP EP06125424A patent/EP1806360A3/en not_active Ceased
- 1997-12-08 BR BR9714004-0A patent/BR9714004A/pt not_active IP Right Cessation
- 1997-12-08 EP EP10184082A patent/EP2287309A1/en not_active Withdrawn
- 1997-12-08 WO PCT/US1997/022740 patent/WO1998026061A2/en not_active Ceased
-
1999
- 1999-06-02 IL IL130247A patent/IL130247A/en not_active IP Right Cessation
- 1999-06-07 NO NO19992756A patent/NO327411B1/no not_active IP Right Cessation
-
2004
- 2004-12-17 US US11/015,117 patent/US7524944B2/en not_active Expired - Fee Related
-
2006
- 2006-09-26 IL IL178306A patent/IL178306A0/en not_active IP Right Cessation
-
2007
- 2007-09-27 NO NO20074906A patent/NO331434B1/no not_active IP Right Cessation
-
2009
- 2009-02-13 US US12/371,188 patent/US7906638B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130247A0 (en) | Novel expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease | |
| TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| IL190793A0 (en) | A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain | |
| CY1106216T1 (el) | 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ | |
| ATE407949T1 (de) | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen | |
| ZA941644B (en) | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof | |
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| ATE299180T1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| PT1232264E (pt) | Gene fgf-21 humano e produtos da expressão do gene | |
| WO2004110345A3 (en) | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same | |
| DE69941330D1 (de) | Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region | |
| DK1000149T3 (da) | 5'-EST'ere til udskilte proteiner identificeret fra hjernevæv | |
| CA2082382A1 (en) | Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy | |
| CY1105398T1 (el) | 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ | |
| DE69635349D1 (de) | Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung | |
| WO2001014420A3 (en) | Novel members of the plexin family and uses thereof | |
| WO2002012285A3 (en) | The tumor suppressor car-1 | |
| MXPA03000979A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
| DE69519924D1 (de) | Gammaglobuline enthaltende immunotherapeutische präparate für die behandlung von krebskrankheiten | |
| DE60019725D1 (de) | Verwendung eines mit dem peptid "elagigiltv" assoziierten enterobakterien-proteins ompa zur behandlung von melanomen | |
| WO1996009391A3 (en) | Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19 | |
| DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
| DE60033540D1 (de) | Verabreichung von gammaglobulinen zur behandlung von lymphomen | |
| IL189190A0 (en) | Use of fluorinated triazoles for treating pain and affective or attention disorders | |
| Taghian et al. | Radiobiological parameters of four glioblastoma compared to four other histological types of human tumor xenografts in nude mice |